» Articles » PMID: 39711788

Association of White Matter Hyperintensities with Lipoprotein (a) Levels: Insights from a Cohort Study

Overview
Journal Front Neurol
Specialty Neurology
Date 2024 Dec 23
PMID 39711788
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Little is known about the relationship between lipoprotein (a) [Lp(a)] and cerebral white matter hyperintensities (WMH). The aim of the study was to examine if elevated Lp(a) levels are associated with higher burden of WMH.

Methods: We retrospectively investigated associations between Lp(a) and the burden of WMH among patients with confirmed diagnosis of acute ischemic stroke or transient ischemic attacks. WMH burden was assessed using 3-Tesla brain MRI and graded according to the Fazekas score. Multivariable models were generated to determine the contribution of Lp(a) to the presence and extent of WMH.

Results: One hundred and fifty-three patients were included (mean age, 45.9 years; 35.9% women). When the study population was stratified by Lp(a) level into three categories, low (<75 nmol/L), moderate (75 to <125 nmol/L), and high (≥125 nmol/L), the distribution of the three groups was 60.8, 15.0 and 24.2%, respectively. High Lp(a) Level was associated with higher burden of both periventricular WMH and deep WMH compared to the lower level (odds ratio [OR], 4.4; 95% confidence interval [CI], 1.60-12.07;  = 0.004; and OR, 5.6; CI, 1.69-14.7;  = 0.001, respectively).

Conclusion: We show in this cohort of patients that a higher burden of WMH was observed in patients with higher level of Lp(a). Further studies are needed to confirm this observation and assess whether lowering Lp(a) level may be a potential therapeutic target for mitigating the development of WMH.

References
1.
Wardlaw J, Smith E, Biessels G, Cordonnier C, Fazekas F, Frayne R . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013; 12(8):822-38. PMC: 3714437. DOI: 10.1016/S1474-4422(13)70124-8. View

2.
Berman A, Biery D, Besser S, Singh A, Shiyovich A, Weber B . Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024; 83(9):873-886. DOI: 10.1016/j.jacc.2023.12.031. View

3.
Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R . MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987; 149(2):351-6. DOI: 10.2214/ajr.149.2.351. View

4.
Kamstrup P . Lipoprotein(a) and Cardiovascular Disease. Clin Chem. 2020; 67(1):154-166. DOI: 10.1093/clinchem/hvaa247. View

5.
Liu Y, Yuan C, Chen X, Fang X, Hao J, Zhou M . Association of Plasma Lipids with White Matter Hyperintensities in Patients with Acute Ischemic Stroke. Int J Gen Med. 2023; 16:5405-5415. PMC: 10676100. DOI: 10.2147/IJGM.S440655. View